Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | PPARG | P37231 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.79 |
| ▸ | PKM | P14618 | 2/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | THPO | P40225 | 1/20 | 0.79 |
| ▸ | MTOR | P42345 | 1/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369092 | 0.89 | RORC (1.00) | RORCKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL420231 | 0.89 | RORC (1.00) | RORCKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL27676843 | 0.87 | MEN1 (0.74) | RORCKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL7129256 | 0.86 | RORC (0.85) | RORCKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL7125062 | 0.86 | RORC (0.85) | RORCKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL7130609 | 0.86 | RORC (0.84) | RORCKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL11911348 | 0.85 | MAPT (0.76) | RORCKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL19066460 | 0.84 | MAPT (1.00) | RORCKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL18147432 | 0.83 | RORC (0.80) | RORCKMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL7121705 | 0.83 | RORC (0.80) | RORCKMT2ASMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1289072-C | Aniline derivatives or salts thereof and cytokine prodn inhibitors contg. same | ISHIHARA SANGYO KAISHA (JP) | 2006-12-13 | — | — | CN | disclosed |
| US-7132546-B2 | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20040048891-A1 | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| CN-1481238-A | Aniline derivative or salt thereof and cytokine production inhibitor containing the same | 石原产业株式会社 | 2004-03-10 | — | — | CN | disclosed |
| EP-1344525-A1 | ANILINE DERIVATIVES OR SALTS THEREOF AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THE SAME | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048891-A1 | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same | IL2, IL4I1, IFNG | RORC 726/4885KMT2A 3083/4885SMN1; SMN2 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.